Funded Projects › FP7
PLASTICISE · Promotion of plasticity as a treatment for neurodegenerative conditions
Neurodegenerative diseases all cause damage to the circuitry of the nervous system, with loss of connections, axons and neurons. The loss can be gradual, as in Alzheimer’s disease, rapid as in stroke, or intermediate as in the delayed neuronal loss after stroke. Following damage, the nervous system is able partially to compensate through the formation of alternative connections and pathways, a process known as plasticity. Adults are therefore able to regain considerable function after stroke, and to compensate for the synapse and cell loss of Alzheimer’s disease until it reaches a critical level. Children undergo a period of enhanced plasticity in most parts of the CNS at the end of development, known as critical periods. During these periods their ability to compensate for damage to the CNS is in many cases much greater than in adults. The overall concept behind this application is that restoration of the function in neurodegeneration can be achieved through plasticity (the formation of new functional connections, withdrawal of inappropriate connections, modulation of synaptic strength). Promoting increased plasticity in selected parts of the adult nervous system back to the level seen in children is a powerful method of enhancing recovery of function in animal models. Plasticity-promoting treatments could therefore be beneficial in a wide range of conditions that damage the CNS. The PLASTICISE project integrates scientists from four scientific areas 1) Development of methods to promote plasticity 2) Development of models of neurodegenerative disease 3) Imaging of plasticity at the macro and micro level 4) Study of recovery of function through plasticity in human patients with brain disorders. The concept that unites the partners is the belief that treatments that enhance plasticity will become one of key medications that will improve neurological function in the damaged human nervous system. The purpose of the project is to bring this moment closer.
Consortium · 16 organisations
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
UK · €871,932
Novartis Forschungsstiftung
CH · €338,930
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
UK · €2,400
D-Pharm LTD
IL · €14,400
UNIVERSITE DE GENEVE
CH · €338,930
KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW
NL · €301,130
NOVARTIS PHARMA AG
CH · €2,400
DANDO WEISS & COLUCCI LIMITED
UK · €229,500
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
CH · €338,930
PHARMAXON SAS
FR · €53,655
University of Zurich
CH · €694,760
CONSIGLIO NAZIONALE DELLE RICERCHE
IT · €338,360
INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK
PL · €330,338
UNIVERSITY COLLEGE LONDON
€641,060
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
DE · €351,440
UNIVERSITAETSKLINIKUM FREIBURG
DE · €351,280
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.